



**BioVentures Institute Sp. z o.o. (Ltd.)**

Promienista 83 street  
60-141 Poznań  
Poland

## LETTER OF INTENT

Dear Sir or Madam:

This letter is to confirm that the Bioventures Institute Ltd. is highly interested in using the technology performed by amide hydrogen/deuterium (H/D) exchange in solution coupled mass spectrometry (HDXMS) for the purpose of analysing protein-DNA interaction of mutant restriction endonucleases, belonging to the group of 'ultra-frequent cutters'. Such enzymes are uniquely suited for construction of representative genomic libraries. Currently, substantial research and commercial efforts are directed toward personalised medicine, based in part on sequencing an individual's genome or its fragments. Rational design of such enzymes would greatly enhance developing of various DNA-recognition specificities, thus allowing for construction of representative, overlapping genomic libraries.

For your information, BioVentures Institute, founded in 2009 in Poznan (Poland), developed universal technology (NextGenVac™) for the construction of recombinant polyepitopic antigens to be used as preventive and therapeutic vaccines of new generation. The resulting new vaccine type has the theoretical potential to stimulate the immune system response a hundred times more strongly than the currently used vaccines. New vaccines will be generated with the use of novel, dedicated genetic engineering methodology, based on a specialized and custom developed vector-enzymatic system, generating hiperimmunogenic antigens. Initial in vitro tests, using model HBV viral antigens confirmed the theoretical predictions and validated the vector-enzymatic DNA amplification system. The proposed technology is applicable to most of the antigen targets, including viruses and other microorganisms. After minor modification the technology is applicable to construct vaccines against bacteria and cancer. The technology is protected worldwide by 9 patent applications.

This letter indicates our willingness to future cooperation and signing a partnership agreement, determining detailed rights and duties of contracting partners.

Sincerely,

Prof. Piotr Skowron, Ph.D., D.Sc.  
President BioVentures Institute Ltd.